Media
Penn dementia expert on newly approved Alzheimer’s drug: ‘The data aren’t strong enough
Dr. Jason Karlawish speaks to the Philadelphia Inquirer about Biogen and the new “Alzheimer’s drug.” "It's not even certain that the drug works," Dr. Karlawish said.
Landmark Alzheimer’s drug approval confounds the research community
Many scientists say there is not enough evidence that Biogen’s aducanumab is an effective therapy for the disease. Dr. Jason Karlawish is among them in this Nature interview.
Alzheimer’s Drug Approval Draws Fire on Treatment’s Effectiveness and Uses
U.S. approval of a medication that removes a key marker for Alzheimer’s disease sharply divided clinicians and advocates over whether it has the ability to change the disease’s progress and how it will be used. Read more for Dr. Jason Karlawish’s thoughts.
Biogen’s Alzheimer’s Drug Is Approved by the FDA. The Price? $56,000 a Year.
Dr. Jason Karlawish and other experts talk to Barrons about Biogen and Aducanumab in light of its FDA approval.
Biogen's Alzheimer's drug wins FDA approval
After months of anticipation, Biogen Inc. (Nasdaq: BIIB) has won a coveted — but controversial — approval from the U.S. Food and Drug Administration for aducanumab, its blockbuster drug to treat early-onset Alzheimer's disease.
FDA approves the first drug intended to slow cognitive decline caused by Alzheimer’s disease
Dr. Jason Karlawish speaks to the Washington Post about the hotly debated approval, the first for the illness in almost two decades, but he says evidence of effectiveness is scant.
A Highly Controversial Alzheimer’s Treatment Won FDA Approval. Scientists Say We Don’t Know If It Actually Works.
In one sense, aducanumab is a historic drug — but many scientists say its approval is a triumph of business interests over public health. Dr. Jason Karlawish speaks about his history and future with the drug.
Alzheimer’s Drug Poses a Dilemma for the F.D.A.
If the agency approves it, aducanumab would be the first new Alzheimer’s treatment since 2003. Patients are desperate for new options, but some scientists say there isn’t enough evidence it works.
Hidden Helpers: Unpaid Caregivers And The Pandemic
Dr. Jason Karlawish is a featured guest in this episode of NPR’s 1A podcast. Throughout the episode, Dr. Karlawish provides a physician’s perspective on this healthcare crisis to host Kathryn Fink.
Dr. Jason Karlawish: A Q&A About Alzheimer’s and His New Book
June 1st is the start of Brain Health Awareness Month and WAM decided to interview Dr. Jason Karlawish, author of The Problem of Alzheimer’s, about the history of Alzheimer’s and what it means for families everywhere.
If the FDA approves Biogen’s Alzheimer’s treatment, I won’t prescribe it
You might think that I’m among those hoping the FDA will approve aducanumab, an experimental Alzheimer’s drug developed by Biogen. But I’m not. Why? Biogen hasn’t made a convincing case for it.
C-SPAN2 Book tv - the problem of alzheimer’s
Richard James hosts this Penn Biomedical Library event where Dr. Jason Karlawish traces the history of Alzheimer’s disease, from early disease recognition to its growth into one of the world’s most prevalent illnesses.
Sparks of Clarity - A Penn Medicine Listening Lab Story Experience
Dr. Jason Karlawish shares "Sparks of Clarity," in this storytelling interview with Penn Medicine’s Listening Lab to tell a story with humility and honesty to challenge societal assumptions about Alzheimer's.
Mild Cognitive Impairment Vs. Dementia Vs. Alzheimer's and What We Can Do About Them with Dr. Jason Karlawish
With so many questions about the difference between mild cognitive impairment versus dementia versus Alzheimer's Disease, Dr. Jason Karlawish provides answers and share tips for staving off dementia when you have mild cognitive impairment.
Jason Karlawish and an Alzheimer’s caregiver on dementia’s ripple effect
Dr. Jason Karlawish is featured in this episode of “First Opinion Podcast.” Jason and host Patrick Skerrett were joined by Richard Bartholomew, a husband and caretaker. Both share the isolating, all-encompassing experience of caring for a loved one with Alzheimer’s or other type of dementia.
Jason Karlawish’s ‘The Problem of Alzheimer’s’ Makes Us Mad—In a Good Way
A new book by Dr. Jason Karlawish, The Problem of Alzheimer’s, shares largely untold stories of the history of the Alzheimer’s crisis, discussing the science, the missed opportunities, and the reasons for hope. But, as Phil Gutis writes, it may also make you angry.
Launching the chronicle of a disease of autonomy: PMC hosts book release event for Jason Karlawish’s ‘The Problem of Alzheimer’s’
Dr. Karlawish read an excerpt from his book and answered questions about the revolutionary moments of Alzheimer’s disease history at a virtual launch event hosted by PMC. Watch the event recording here.
The Humanist Is In
An overview of Dr. Jason Karlawish’s nonfiction narrative, The Problem of Alzheimer’s. Julia Klein questions Karlawish in this intensive Q&A that highlights the fragility of science and Alzheimer’s disease.
A Revolution Is Underway in Alzheimer's, and It's Not All Good
The biomarker revolution has changed the way people look at Alzheimer's disease -- and that has its downsides, says Dr. Jason Karlawish, MD, co-director of the Penn Memory Center in this interview with Judy George from Med Page Today.
Episode 20 – Dr. Jason Karlawish and the problem of Alzheimer’s
Rosanne Corcoran, host and creator of Daughterhood, interviews Dr. Jason Karlawish for the 20th episode of her podcast where they deep dive into the historical complexities of Alzheimer’s Disease and the consistent uphill battle that faces those caregivers who provide for the again adult population.
A Geripal Podcast focusing on Jason Karlawish and the problem of alzheimer’s
GeriPal hosts Eric Widera and Alex Smith talk with Dr. Jason Karlawish, about his new book to answer questions such as “Where are we with Alzheimer’s.”
‘The Problem of Alzheimer’s’ Book Excerpt
Dr. Jason Karlawish provides the Women’s Alzheimer’s Movement an exclusive exert of “The Problem of Alzheimer’s” that takes a look inside laboratories, patients’ homes, caregivers’ support groups, progressive care communities. Read the excerpt below.
A Revolution Is Underway in Alzheimer's, and It's Not All Good
Dr. Jason Karlawish dives into the specifics of the history of Alzheimer’s disease in this interview with Judy George. Together they navigate the complexities of this medical field - acknowledging that science often collides with politics. And after decades people with Alzheimer's still have no effective treatments.
HOW SOCIETY CAN IMPROVE CARE FOR PEOPLE WITH ALZHEIMER’S DISEASE AND RELATED DEMENTIAS
Dr. Jason Karlawish discusses society’s role in addressing care for individuals with memory loss, as well as current stigmas around Alzheimer’s, Wealthcare, and his cautious optimism for the future.